Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
Biogen Inc. BIIB shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation f...
![]()
Biotech Industry
The latest biotech headlines from MarketWatch.
Rocket Pharmaceuticals shares rise on FDA fast-track designation for heart disease treatment
Shares of Rocket Pharmaceuticals RCKT gained 2.3% premarket on Thursday after the late-stage biotech company said the U.S. Food and Drug Administra...
Coya Therapeutics stock gains on new data from Alzheimer’s study
Shares of Coya Therapeutics Inc. COYA gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a study of ...
FibroGen shares slide after Duchenne muscular dystrophy treatment falls short in trial
Shares of FibroGen Inc. FGEN were down 5.6% premarket on Wednesday after the company announced disappointing results from a late-stage trial of pa...
Ultragenyx, Mereo shares gain after positive results from study of bone disorder treatment
Shares of Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group PLC MREO gained premarket on Tuesday after the companies on Monday announce...
Most Popular
More Biotech Headlines
Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial
Shares of Bellerophon Therapeutics Inc. BLPH plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoint in a Phase 3 “Rebuild” study...
Debt-ceiling deal: Here’s what’s next as Senate prepares to vote
President Joe Biden and House Speaker Kevin McCarthy struck a debt-ceiling deal over Memorial Day weekend, and the House passed the bill on Wednesday.
‘Don’t Call Me Karen’: Uber diversity head suspended over events highlighting white women’s struggles
Bo Young Lee, Uber's head of diversity, equity and inclusion, was suspended after employees complained of personnel events that gave white women a spotlight.
You can’t rely on indexes to pick international stocks, this 5-star fund manager says. Here are 3 of his top selections.
Krishna Mohanraj of Diamond Hill Capital Management says investors should focus on quality, rather than regional or sector approaches take by stock indexes.
Pay ranges in job listings are widening. It’s a ‘double-edged sword’ for job seekers, one economist says.
Pay-transparency laws can provide insight for job seekers, but listed pay ranges for some jobs are getting wider.
Illumina shareholders vote to elect one of Carl Icahn’s candidates to its board after proxy fight
Illumina Inc. ILMN shareholders voted Thursday to elect one of activist investor Carl Icahn’s nominees to its board, and voted against the re-election of company Chairman John Thompson, according to media reports on Thursd...
Yellen says she’s worried about ‘substantial financial-market distress’ even when there’s a debt-ceiling deal
U.S. Treasury Secretary Janet Yellen talks about Washington's debt-ceiling standoff during The Wall Street Journal’s CEO Council Summit.
Sarepta says FDA is working toward accelerated approval of its latest treatment for Duchenne muscular dystrophy
Sarepta Therapeutics Inc. SRPT said Wednesday that the U.S. Food and Drug Administration has indicated after talks with the company that it’s working toward granting accelerated approval of SRP-9001, its latest treatment f...
Achieve Life Sciences says confirmatory late-stage trial of its treatment for quitting smoking achieved positive results
Achieve Life Sciences Inc. ACHV said Tuesday a second confirmatory late-stage trial of its cytisinicline for quitting smoking and nicotine dependence achieved positive results, showing a statistically significant benefit c...
House-flipping influencer and life coach hit with hefty fines in bogus $400 million training program and 5 hottest metros are in the south
Monday's top personal finance stories.
Intercept Pharmaceuticals stock tumbles toward 11-month low after disappointing FDA committee vote
Shares of Intercept Pharmaceuticals Inc. ICPT tumbled 15.2% toward an 11-month low in premarket trading Monday, after the biopharmaceutical company said a U.S. Food and Drug Administration committee voted to “defer approva...
Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
Ironwood Pharmaceuticals Inc. IRWD said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT for $17 a share in cash, or a total of about $1 billion, net of VectivBio’s cash and debt. The price is equal ...
Krystal Biotech stock rises after FDA approves treatment for rare skin disease
Krystal Biotech Inc. KRYS shares rose Friday after the biotech drug company received Food and Drug Administration approval of a rare skin disease treatment. Krystal shares rose as much as 8% to an intraday high of $94.61 a...
Why is Elizabeth Holmes going to prison? A recap of how the Theranos founder got here
Holmes, who was convicted of defrauding Theranos investors, is set to begin her 11-year prison sentence on May 30.
Corrected Here’s the big thing holding up the stock market, says Bank of America
Investors want to see the economy land softly softly, and that is the main thing that will keep assets resilient, say BofA managers.
Horizon shares sink on report that FTC will sue to block takeover by Amgen
Shares of Horizon Therapeutics Inc. plunged 15% in extended trading Monday after Bloomberg News reported the FTC is expected to file a lawsuit to block Amgen Inc.'s $27.8 billion acquisition of Horizon.
Athenex files for Chapter 11 seeking buyer for its drug candidates
Athenex Inc. ATNX, a biotech that specializes in cancer treatments, said late Sunday it has filed for Chapter 11 bankruptcy with an agreement with lenders to pursue an expedited sale of its assets. The company is expecting...
Sarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapy
Sarepta Therapeutics Inc.’s stock SRPT soared 30% premarket Monday, after a U.S. Food and Drug Administration panel voted 8-6 in favor of accelerated approval for the company’s latest gene therapy for Duchenne muscular dy...
Sarepta Therapeutics stock halted premarket ahead of FDA panel meeting on new Duchenne muscular dystrophy treatment
Sarepta Therapeutics Inc. stock SRPT was halted premarket Friday, ahead of a meeting of a Food and Drug Administration advisory panel to discuss the company’s SRP-9001 gene therapy for the rare genetic disorder Duchenne mu...
ImmunityBio stock loses more than half its value after disclosing FDA can’t approve the BLA for its cancer treatment in its present form
Shares of ImmunityBio Inc. IBRX plummeted 53.7% toward a record one-day selloff in premarket trading Thursday, after the immunotherapy company disclosed it received a “complete response letter” from the U.S. Food and Drug ...
